TG Therapeutics (TGTX) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Goldman Sachs Upgrades TG Therapeutics (TGTX) to Neutral, 'Valuation reflects Briumvi outlook'
August 2, 2023 7:09 AM EDTGoldman Sachs analyst Corinne Jenkins upgraded TG Therapeutics (NASDAQ: TGTX) from Sell to Neutral with a price target of $12.00 (from $16.00).
The analyst comments "We upgrade TGTX to Neutral from Sell and lower our 12-month price target to $12 ($16 prior). TGTX shares closed -50% (vs. XBI -1.2%) following 2Q23 EPS, which included revenue of $16.0M, well... More
TG Therapeutics (TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI
August 1, 2023 7:28 AM EDTTG Therapeutics (NASDAQ: TGTX) Falls 45% Following Earnings, Ex-US Commercialization Agreement for BRIUMVI
... More